Jump to content
Powered by

Selected press releases

  • Press release - 24/05/2017

    High-Tech Gründerfonds is investing EUR 600,000 in Reutlingen-based SIGNATOPE GmbH. SIGNATOPE will use the funds to advance the development of its unique biomarker assay system, that has been established to support pharmaceutical research. The technology is based on special antibodies and allows the early detection of possible side effects during the drug development process. Thereby, the need for animal testing will be reduced while the drug…

  • Press release - 23/05/2017

    TolerogenixX GmbH has developed a patented and clinically tested cell therapy technique for individualised immunosuppression in transplant patients. The technique enables the targeted disabling of undesired reactions caused by the immune system’s defences. As a seed stage investor, High-Tech Gründerfonds (HTGF) will finance this innovative technique and the preparations for Phase II of the clinical trial, which begins in spring 2018. Further…

  • Press release - 07/02/2017

    The next generation of Antiviral Therapies: Led by Stichting Participatie Atriva together with High-Tech Gründerfonds (HTGF), Atriva Therapeutics GmbH has received seed financing from Dutch and German private investors to advance Atriva’s antiviral MEK-Inhibitors (Mitogen-activated protein kinase kinase inhibitor) against Influenza into the clinical development stage.

  • Press release - 31/01/2017

    Researchers of Karlsruhe Institute of Technology (KIT) have developed a new fluorescence microscopy method: STEDD (Stimulation Emission Double Depletion) nanoscopy produces images of highest resolution with suppressed background. The new method yields an enhanced image quality, which is advantageous when analyzing three-dimensional, densely arranged subcellular structures. STEDD, a further development of the STED method, is now presented in…

  • Press release - 30/01/2017

    ChemCon GmbH, service provider for custom development and custom manufacturing of active pharmaceutical ingredients (APIs) and fine chemicals, based in the Innovationspark (innovations park) Freiburg, Germany, celebrates its 20th anniversary. On January 29 in 1997, Dr. Raphael Vogler (CEO) and Dr. Peter Gockel (CSO), both graduates from the Albert-Ludwigs-University Freiburg, signed the partnering contract to found ChemCon. Today they count 90…

  • Press release - 24/01/2017

    The European Research Council awards Wilfried Weber an ERC Proof of Concept Grant. Wilfried Weber, Professor of Synthetic Biology at the University of Freiburg, has received a grant of roughly €150,000 for his project “Hide and Seek with Cancer Drugs” in which he is working to improve the drugs used in cancer treatment.

  • Press release - 05/01/2017

    Phenex Pharmaceuticals AG (Phenex) today announced that the company has received a 100 M USD milestone payment from Gilead Sciences, Inc. of Foster City, CA, U.S.A., for its program with GS-9674 targeting nonalcoholic steatohepatitis (NASH).

Website address: https://www.gesundheitsindustrie-bw.de/en/article/press-release